Functional Gastrointestinal Disorders Therapeutics
1. Ibsrela patent expiration
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(3 years from now) | |
| US12016856 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(3 years from now) | |
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(4 years from now) | |
| US9408840 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
Dec, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Dosage: TABLET
More Information on Dosage
IBSRELA family patents
2. Linzess patent expiration
Treatment: Method of treating chronic idiopathic constipation in adult patients.; Method of treating of irritable bowel syndrome with constipation (ibs-c) in pediatric patients 7 years of age and older; Method o...
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7304036 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(7 months from now) | |
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 11 months ago) | |
| US8933030 | ABBVIE | Treatments for gastrointestinal disorders |
Feb, 2031
(5 years from now) | |
| US8748573 | ABBVIE | Formulations comprising linaclotide |
Oct, 2031
(5 years from now) | |
| US9708371 | ABBVIE | Treatments for gastrointestinal disorders |
Aug, 2033
(7 years from now) | |
| US10702576 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
| US8802628 | ABBVIE | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(5 years from now) | |
| US10675325 | ABBVIE | Stable formulations of linaclotide |
Aug, 2031
(5 years from now) | |
|
US8802628 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US7304036 (Pediatric) | ABBVIE | NA |
Feb, 2027
(1 year, 1 month from now) | |
|
US8748573 (Pediatric) | ABBVIE | NA |
Apr, 2032
(6 years from now) | |
|
US9708371 (Pediatric) | ABBVIE | NA |
Feb, 2034
(8 years from now) | |
|
US8933030 (Pediatric) | ABBVIE | NA |
Aug, 2031
(5 years from now) | |
|
US10675325 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
|
US10702576 (Pediatric) | ABBVIE | NA |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
3. Viberzi patent
expiration
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); Re...
VIBERZI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10213415 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US9115091 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(2 years from now) | |
| US8691860 | ABBVIE | Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(2 years from now) | |
| US8609709 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US7786158 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US7741356 | ABBVIE | Compounds as opioid receptor modulators |
May, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8772325 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US9364489 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(2 years from now) | |
| US9789125 | ABBVIE | Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
Jul, 2028
(2 years from now) | |
| US8344011 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US12097187 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US9205076 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US11484527 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US9675587 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US11007179 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US9700542 | ABBVIE | Compounds as opioid receptor modulators |
Mar, 2025
(9 months ago) | |
| US11090291 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US11311516 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US11229627 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US10188632 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| US11160792 | ABBVIE | Opioid receptor modulator dosage formulations |
Mar, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2020 |
Drugs and Companies using ELUXADOLINE ingredient
NCE-1 date: 28 May, 2019
Market Authorisation Date: 27 May, 2015
Dosage: TABLET
How can I launch a generic of VIBERZI before it's drug patent expiration?
More Information on Dosage
VIBERZI family patents
4. Xifaxan patent expiration
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; ...
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741904 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(a month from now) | |
| US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(1 year, 7 months from now) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 6 months ago) | |
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456384 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US10335397 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9421195 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8946252 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US7452857 | SALIX PHARMS | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US8829017 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US8642573 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(3 years from now) | |
| US10314828 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US7915275 | SALIX PHARMS | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(10 months ago) | |
| US7605240 | SALIX PHARMS | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US7935799 | SALIX PHARMS | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US10709694 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US10765667 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US8969398 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(3 years from now) | |
| US6861053 | SALIX PHARMS | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Aug, 2019
(6 years ago) | |
| US8518949 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(a month from now) | |
| US9629828 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US9271968 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(a month from now) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 6 months ago) | |
| US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(1 year, 7 months from now) | |
| US10703763 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(a month from now) | |
| US7718608 | SALIX PHARMS | Methods of treating a subject suffering from irritable bowel syndrome |
Aug, 2019
(6 years ago) | |
| US8309569 | SALIX PHARMS | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(3 years from now) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 6 months ago) | |
| US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(7 months ago) | |
| US7928115 | SALIX PHARMS | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(3 years from now) | |
| US11779571 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| US11564912 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
5. Zelnorm patent expiration
Treatment: Treatment of irritable bowel syndrome
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5510353 | ALFASIGMA | Certain aminoguanidine compounds, pharmaceutical compositions containing them and their use in treating gastrointestinal motility disorders and disorders associated with cephalic pain |
Apr, 2013
(12 years ago) | |
Drugs and Companies using TEGASEROD MALEATE ingredient
Market Authorisation Date: 24 July, 2002
Dosage: TABLET
More Information on Dosage
ZELNORM family patents